HIGHLIGHTS
- who: August et al. from the Changzhou Institute of Technology, China Peking University Third, China have published the Article: Ef cacy, safety, and cost-effectiveness analysis of a ibercept in metastatic colorectal cancer: A rapid health technology assessment, in the Journal: (JOURNAL) of 13/02/2018
- what: This study provides crucial evidence for the approval of aflibercept combined with FOLFIRI for secondline treatment in patients with metastatic colorectal cancer who progressed or were resistant to oxaliplatin after oxaliplatin treatment. The analysis showed that in Japan, the combination of aflibercept or ramucirumab with FOLFIRI was not . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.